{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:37:06Z","timestamp":1760747826120,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejca.2023.113255","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T14:35:05Z","timestamp":1692196505000},"page":"113255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma"],"prefix":"10.1016","volume":"192","author":[{"given":"Rachel S.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8984-1249","authenticated-orcid":false,"given":"Joy","family":"Justice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0256-0516","authenticated-orcid":false,"given":"Reena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Dewan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113255_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.03.011","article-title":"Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma","volume":"132","author":"Hemstock","year":"2020","journal-title":"Eur J Cancer"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2023.113255_bib2","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113255_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113255_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"10.1016\/j.ejca.2023.113255_bib5","first-page":"4073","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113255_bib6","first-page":"345","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am\u00a0J\u00a0Clin\u00a0Dermatol"},{"key":"10.1016\/j.ejca.2023.113255_bib7","first-page":"190","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur\u00a0J\u00a0Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.113255_bib8","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1111\/jdv.18780","article-title":"Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab","volume":"37","author":"Hansen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.ejca.2023.113255_bib9","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1007\/s00520-021-05993-5","article-title":"Oral mucositis\u2014case series of a rare adverse effect associated with immunotherapy","volume":"29","author":"Sheth","year":"2021","journal-title":"Support\u00a0Care Cancer"},{"key":"10.1016\/j.ejca.2023.113255_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/11795549211028570","article-title":"Immunotherapy-related gastritis: two case reports and literature review","volume":"15","author":"Woodford","year":"2021","journal-title":"Clin Med Insights Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:58Z","timestamp":1760733658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":10,"alternative-id":["S095980492300357X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113255","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113255"}}